-transparent.png){kind=logo}
The arrhythmogenic effects of flecainide in atrial fibrillation and flutter were assessed in a consecutive material of 100 patients without severe heart failure (NYHA class I or II). Severe arrhythmogenic events occurred in 9% (4-16%) of the patients: within the first 5 days of treatment in seven patients, and in two patients after 60 and 240 days of flecainide treatment. Patients with proarrhythmic events tended to be older and to have a longer QRS duration. Following flecainide therapy conversion to sinus rhythm was achieved in 21 of 43 patients (49%) with atrial fibrillation and in 10 of 29 (34%) with atrial flutter. It is concluded that flecainide, although an effective antiarrhythmic drug, has potential proarrhythmic effects and therefore cautious use of this drug is mandatory.
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
June 1985,
The New Zealand medical journal,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
May 1985,
The New Zealand medical journal,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
January 1990,
Cardiology,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
January 1996,
The American journal of cardiology,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
December 1989,
The American journal of cardiology,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
January 1996,
Ryoikibetsu shokogun shirizu,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
April 1991,
The American journal of cardiology,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
June 1987,
The American journal of cardiology,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
March 1993,
European heart journal,
I Sihm, and
F A Hansen, and
J Rasmussen, and
A K Pedersen, and
K Thygesen
August 1992,
The American journal of cardiology,
